Highlights Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-26 pm EDT			5-day change	1st Jan Change
39.38 ^CNY	+1.81%		+0.25%	+12.48%

01:55pm	Livzon Pharmaceutical Cancels 5.3 Million Share Options	MT
May. 14	Livzon Pharmaceutical Group Cancels Share Options	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Livzon Pharmaceutical Cancels 5.3 Million Share Options	07:55am	MT
Livzon Pharmaceutical Declares Final Dividend for 2023	May. 13	MT
Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	Apr. 26	CI
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	Apr. 24	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.	Apr. 02	CI
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	Mar. 29	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	Mar. 28	CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	Feb. 23	MT
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	Feb. 22	CI
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	Jan. 18	CI
Livzon Pharma Recognizes Credit, Asset Impairments	Jan. 10	MT
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics	Dec. 18	MT
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List	Dec. 14	MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	Dec. 04	MT
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use	Dec. 03	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 5% stake in Zhuhai Livzon Diagnostics Inc. from Shi Jianfeng.	Nov. 20	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin.	Nov. 20	CI
Livzon Pharma Boosts Stake in Diagnostic Equipment Unit Ahead of Spinoff	Nov. 20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

Highlights

Filters